XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 6,954 | $ 6,599 | $ 13,640 | $ 12,951
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,941 | 4,784 | 9,574 | 9,236
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,133 | 1,027 | 2,292 | 2,106
Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 879 | 789 | 1,774 | 1,610
Total product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 6,912 | 6,564 | 13,559 | 12,870
Total product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,916 | 4,777 | 9,525 | 9,211
Total product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 1,118 | 999 | 2,262 | 2,052
Total product sales | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 878 | 788 | 1,772 | 1,607
Total HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 4,745 | 4,626 | 9,088 | 8,816
Total HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,821 | 3,778 | 7,226 | 7,142
Total HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 571 | 521 | 1,167 | 1,049
Total HIV | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 353 | 326 | 695 | 624
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3,232 | 2,979 | 6,177 | 5,656
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 2,585 | 2,439 | 4,900 | 4,600
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 370 | 302 | 735 | 606
Biktarvy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 277 | 237 | 542 | 449
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 485 | 516 | 911 | 965
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 434 | 460 | 805 | 855
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 25 | 51 | 50
Descovy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 31 | 55 | 60
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 440 | 540 | 843 | 1,041
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 372 | 455 | 704 | 872
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 45 | 56 | 95 | 111
Genvoya | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 23 | 29 | 44 | 58
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 315 | 351 | 626 | 668
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 233 | 267 | 457 | 497
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 72 | 74 | 148 | 149
Odefsey | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 10 | 11 | 21 | 22
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 168 | 120 | 309 | 259
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 131 | 84 | 236 | 182
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 34 | 33 | 67 | 70
Revenue share - Symtuza | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 3 | 3 | 6 | 7
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 105 | 120 | 222 | 228
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 74 | 125 | 136
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 31 | 70 | 63
Other HIV | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 15 | 27 | 28
Total Liver Disease |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 832 | 711 | 1,569 | 1,386
Total Liver Disease | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 431 | 356 | 816 | 674
Total Liver Disease | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 142 | 131 | 279 | 271
Total Liver Disease | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 259 | 225 | 474 | 441
Sofosbuvir/Velpatasvir |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 476 | 397 | 881 | 782
Sofosbuvir/Velpatasvir | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 267 | 223 | 515 | 427
Sofosbuvir/Velpatasvir | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 84 | 84 | 163 | 174
Sofosbuvir/Velpatasvir | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 126 | 90 | 203 | 181
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 243 | 219 | 467 | 418
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 117 | 96 | 212 | 183
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 11 | 10 | 22 | 19
Vemlidy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 115 | 113 | 233 | 216
Other Liver Disease |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 113 | 95 | 221 | 186
Other Liver Disease | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 47 | 37 | 89 | 64
Other Liver Disease | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 47 | 37 | 94 | 78
Other Liver Disease | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 19 | 21 | 38 | 44
Veklury |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 214 | 256 | 769 | 829
Veklury | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 76 | 97 | 391 | 349
Veklury | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 53 | 52 | 123 | 163
Veklury | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 85 | 107 | 255 | 317
Total Oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 841 | 728 | 1,629 | 1,398
Total Oncology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 474 | 462 | 904 | 893
Total Oncology | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 275 | 215 | 537 | 417
Total Oncology | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 92 | 51 | 188 | 88
Total Cell Therapy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 521 | 469 | 1,001 | 916
Total Cell Therapy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 250 | 272 | 475 | 542
Total Cell Therapy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 206 | 162 | 400 | 310
Total Cell Therapy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 66 | 34 | 126 | 65
Tecartus |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 107 | 88 | 207 | 177
Tecartus | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 63 | 56 | 118 | 114
Tecartus | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 37 | 29 | 73 | 56
Tecartus | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 7 | 4 | 16 | 6
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 414 | 380 | 794 | 739
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 186 | 217 | 357 | 427
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 169 | 133 | 327 | 254
Yescarta | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 58 | 30 | 110 | 58
Trodelvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 320 | 260 | 628 | 482
Trodelvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 224 | 189 | 429 | 351
Trodelvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 69 | 53 | 137 | 107
Trodelvy | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 26 | 17 | 62 | 23
Total Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 280 | 243 | 504 | 442
Total Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 115 | 85 | 188 | 153
Total Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 77 | 80 | 156 | 152
Total Other | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 88 | 78 | 160 | 137
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 151 | 151 | 294 | 267
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 17 | 20 | 31 | 27
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 69 | 69 | 139 | 129
AmBisome | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 65 | 61 | 124 | 111
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 130 | 92 | 209 | 175
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 98 | 64 | 156 | 127
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 8 | 10 | 18 | 22
Other | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 24 | 17 | 36 | 26
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 41 | 35 | 81 | 81
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 25 | 6 | 49 | 25
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | 15 | 28 | 30 | 54
Royalty, contract and other revenues | Rest of World |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Total revenues | $ 1 | $ 1 | $ 2 | $ 3

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_RestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsOtherLiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |